Apremilast is suitable as a long-lasting basic treatment for psoriasis that is easy to prescribe in found small clinics and to use in everyday life, a new study found. Researchers reported on the clinical outcomes of administering apremilast for 2 years as observed in 46 Japanese patients with psoriasis. Among the details:
- Drug survival analysis revealed a 1-year continuation rate of 46.8% and a 2-year continuation rate of 37.4%.
- Dermatology Life Quality Index (DLQI) scores during the observation period declined from 9.3 to 2.8 on average.
- Major adverse events with apremilast treatment were diarrhea and nausea, with most cases of diarrhea being mild.
Sarhwatari H. Real-world experiences of apremilast in clinics for Japanese patients with psoriasis. [Published online ahead of print October 6, 2019]. J Dermatol. doi: 10.1111/1346-8138.15104.